Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q7Z4S6
UPID:
KI21A_HUMAN
Alternative names:
Kinesin-like protein KIF2; Renal carcinoma antigen NY-REN-62
Alternative UPACC:
Q7Z4S6; A8MX28; B0I1R9; B9EGE4; F5H0C3; F5H219; Q2UVF1; Q6UKL9; Q7Z668; Q86WZ5; Q8IVZ8; Q9C0F5; Q9NXU4; Q9Y590
Background:
Kinesin-like protein KIF21A, also known as Kinesin-like protein KIF2 and Renal carcinoma antigen NY-REN-62, is a microtubule-binding motor protein. It plays a crucial role in neuronal axonal transport, moving along microtubules with a plus-end directed motor activity. This protein's function is vital for the proper functioning of neuronal cells.
Therapeutic significance:
KIF21A is implicated in congenital fibrosis of extraocular muscles type 1, a disorder characterized by restrictive ophthalmoplegia, ptosis, and backward tilt of the head. Understanding the role of Kinesin-like protein KIF21A could open doors to potential therapeutic strategies for this and related ocular motility disorders.